Please login to the form below

Not currently logged in
Email:
Password:

Merck and Co

This page shows the latest Merck and Co news and features for those working in and with pharma, biotech and healthcare.

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Merck &Co/MSD, Janssen and Eli Lilly have all reported similar patterns in earlier failed candidates in the category. ... Biogen and Eisai also had to pull the plug on their phase 3 Alzheimer’s candidate aducanumab earlier this year.

Latest news

  • AZ, Merck’s Lynparza scores market-expanding clinical success AZ, Merck’s Lynparza scores market-expanding clinical success

    trial. AstraZeneca and Merck, which began co-developing Lynparza in 2017 through a deal worth $1.6bn upfront, are yet to share the data from the trial that will reveal a ... That approval and clearances in other indications have turned Lynparza into a

  • Trial backs role for Lynparza in second-line prostate cancer Trial backs role for Lynparza in second-line prostate cancer

    Demonstrates potential significant benefit in treatment of disease. AstraZeneca and Merck &Co/MSD have reported positive phase 3 data for Lynparza in advanced castration-resistant prostate cancer (CRPC), a fourth potential ... eg CDK12) fared less well,

  • Positive first-line phase 3 results for Tecentriq Positive first-line phase 3 results for Tecentriq

    Hopes to extend use in bladder cancer. Roche has revealed that its blockbuster drug Tecentriq (atezolizumab) has met its co-primary endpoint in an ongoing study in bladder cancer, with hopes ... Tecentriq was the third drug to hit the growing PD-1/PD-L1

  • New products help lift Roche outlook despite biosimilar onslaught New products help lift Roche outlook despite biosimilar onslaught

    $787m). Roche now expects to shortly unveil phase 3 results in liver cancer, which will help Tecentriq consolidate its position as the third biggest checkpoint inhibitor behind Merck &Co's Keytruda ... Finally, the period also saw the approval of two new

  • Hal Barron touts new drive to improve GSK’s research output Hal Barron touts new drive to improve GSK’s research output

    In February it also signed a major $4.2bn in-licensing partnership with Germany’s Merck, centred on a potential ‘next big thing’ in oncology, bispecific antibodies. ... GSK won’t be able to catch up with immunotherapy leaders, such as Merck

More from news
Approximately 43 fully matching, plus 456 partially matching documents found.

Latest Intelligence

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    Ex-Merck &Co. scientist Joshua Boger did want the company to pioneer rationale drug discovery and development, however, and after. ... a loss in almost all of its 20+ years, and has cumulative net losses of around $3bn.

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases? ... The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    EvaluatePharma forecasts that Lynparza (now co-marketed with Merck &Co) will hit annual revenues of $2.2bn by 2024, with Imfinzi expected to reach $3.65bn and Tagrisso leading the way ... This gives it a unique niche in an IO lung cancer market dominated

  • Deal Watch October 2018

    The deal between Merck &Co and Samsung Bioepis has been in place since 2013, when Merck &Co began to work with Samsung Bioepis to produce biosimilars. ... Merck &Co has paid $155m to Samsung Bioepis to cover the investments made so far, plus interest, in

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Checkpoint inhibitors – old and new. The first wave of checkpoint inhibitors targeting PD-(L) 1 and CTLA-4, from Bristol-Myers Squibb, Merck &Co, Roche, AstraZeneca and Merck KGaA/Pfizer, have ... Meanwhile, Incyte’s Merck &Co partnered IDO inhibitor

More from intelligence
Approximately 0 fully matching, plus 41 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    Laboratories and Merck &Co. ... to help take Abcam to the next stage in its development and growth.”.

  • Nabriva Therapeutics appoints chief medical officer Nabriva Therapeutics appoints chief medical officer

    Schranz. Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs. ... Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.

  • Hansa Medical poaches Vifor Pharma’s CEO Hansa Medical poaches Vifor Pharma’s CEO

    Tulstrup was most recently CEO of Swiss pharmaceutical group Vifor Pharma and prior to this he served as senior vice president, global franchise head at Shire. ... Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in

  • Astellas promotes Anthony Fiordaliso to VP, Americas finance Astellas promotes Anthony Fiordaliso to VP, Americas finance

    He has been with the pharma company since 2010, when he joined from Schering-Plough (now part of Merck &Co) and subsequently held positions of increasing responsibility. ... In his new role Fiordaliso will report to Stephen Knowles, senior vice president

  • Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel

    is establishing a Science and Technology Committee, which will be chaired by Slaoui. ... Verwiel has also served at Merck &Co, where he was vice president and was general manager at Merck Sharpe Dohme’s operations in the Netherlands.

More from appointments
Approximately 4 fully matching, plus 33 partially matching documents found.

Latest from PMHub

  • Practical Patient Centricity

    Merck &Co, Sanofi and UCB have identified the competitive advantage that patient centricity brings and are leading the way in its practical implementation. ... Patient centricity is the next market access – and will take 10 years to embed”.

  • Digital Marketing is no Substitute for Sound Strategic Marketing

    With a stronger market access focus, companies can create and implement stronger marketing strategies. ... With no prior blueprint on how to ‘go digital’ in their marketing, early pioneer companies such as Merck &Co.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics